Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Keeping Track: We're Back!

The latest drug development news and highlights from our US FDA Performance Tracker.

Performance Tracker Drug Review

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business

Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.

Deals Business Strategies

Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry

Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.

Business Strategies Commercial

Takeda Gets Serious About Regen Medicine With TiGenix Buy

Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.

M & A Regenerative Medicine
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register